Physician profile
Grace Small
NPI 1780030734
$3,408.39
in general payments reported to CMS, 2019-2025
27 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.40 · 2022: $709 · 2023: $807 · 2024: $1,266 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $342.00 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $314.30 | 2022-2025 | Minimed 780g |
| Amgen INC. | $250.89 | 2023-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $247.49 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $205.75 | 2022-2024 | |
| Lilly USA, LLC | $192.86 | 2022-2024 | Jardiance, Humulin, Mounjaro |
| Xeris Pharmaceuticals, INC. | $148.58 | 2022-2024 | Gvoke Hypopen |
| Corcept Therapeutics | $136.38 | 2022-2024 | Korlym |
| Cequr Corporation | $128.69 | 2024-2025 | Cequr Simplicity |
| Mannkind Corporation | $91.54 | 2021-2024 | Afrezza |
| Abbvie INC. | $87.12 | 2022-2024 | |
| Sequel Med Tech, LLC | $79.96 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $79.55 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $57.10 | 2023-2024 | Omnipod |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $55.32 | 2022-2025 | Tirosint, Licart, Flector |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.89 | 2022-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $53.76 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $47.88 | 2024 | Isturisa, Signifor Lar |
| Currax Pharmaceuticals LLC | $42.50 | 2023 | Contrave |
| Amarin Pharma, INC. | $40.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.54 | 2024 | Strensiq |
| Horizon Therapeutics Plc | $23.93 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $22.76 | 2024 | |
| Esperion Therapeutics, INC. | $18.74 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.44 | 2022 | |
| Merck Sharp & Dohme LLC | $15.20 | 2023 | Januvia, Steglatro, Steglujan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.